Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3113-3120

  Richardson, Paul G ^a   Briemberg, Hannah ^b   Jagannath, Sundar ^b   Wen, Patrick Y ^b   Barlogie, Bart ^b   Berenson, James ^b   Singhal, Seema ^b   Siegel, David S ^b   Irwin, David ^b   Schuster, Michael ^b   Srkalovic, Gordan ^b   Alexanian, Raymond ^b   Rajkumar, S Vincent ^b   Limentani, Steven ^b   Alsina, Melissa ^b   Orlowski, Robert Z ^b   Najarian, Kevin ^b   Esseltine, Dixie ^b   Anderson, Kenneth C ^b   Amato, Anthony A ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BORTEZOMIB; CELECOXIB; DESIPRAMINE; FENTANYL; GABAPENTIN; GLUTAMINE; HYDROCODONE; IBUPROFEN; MORPHINE; NORTRIPTYLINE; OXYCODONE; PYRIDOXINE; ROFECOXIB; THIOCTIC ACID; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BOLUS INJECTION; CANCER RELAPSE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES;

EID: 33746010219     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.7779     Document Type: Article

References (20)

1. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
2. Jagannath S, Barlogie B, Berenson J, et al: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165-172, 2004
3. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
4. Pal PK: Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol 39:323-330, 1999
5. Ropper AH, Gorson KC: Neuropathies associated with paraproteinemia. N Engl J Med 338:1601-1607, 1998
6. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
7. Lonial S, Waller EK, Richardson PG, et al: Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106:3777-3784, 2005
8. Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511, 2002
9. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002
10. Papandreou CN, Daliani DD, Nix D, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer, J Clin Oncol 22:2108-2121, 2004
11. Calhoun EA, Welshman EE, Chang CH, et al: Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741-748, 2003
12. Berenson JR, Jagannath S, Barlogie B, et al: Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 104:2141-2148, 2005
13. Dyck PJ, Davies JL, Litchy WJ, et al: Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 49:229-239, 1997
14. Apfel SC, Schwartz S, Adornato BT, et al: Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial - rhNGF Clinical Investigator Group. JAMA 284:2215-2221, 2000
15. Dumitru D, Amato AA, Zwartz MJ: Nerve conduction studies, in Dumitru D, Amato AA, Zwartz MJ (eds): Electrodiagnostic Medicine (ed 2). Philadelphia, PA, Hanley & Belfus, 2002, pp 159-223
16. Fromme EK, Eilers KM, Mori M, et al: How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30, J Clin Oncol 22:3485-3490, 2004
17. Zangari M, Barlogie B, Hollmig K, et al: Marked activity of Velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM). Blood 104:413a-414a, 2004 (abstr)
18. Jagannath S, Durie BG, Wolf J, et al: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776-783, 2005
19. Oakervee HE, Popat R, Curry N, et al: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129:755-762, 2005
20. San Miguel JF, Richardson P, Sonneveld P, et al: Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial. Blood 106:366a, 2005 (abstr)